(CANCER RESEARCH 50. 2139-2145. April I, I990|
Residual Damage in Mouse Lungs at Long Intervals after Cyclophosphamide
Treatment1
Elizabeth L. Travis,2 Luc Bucci, and Mao-Zhong Fang
Department of Experimental Radiotherapy, The University of Texas M. D. Anderson Cancer Center. Houston, Texas 77030 ¡E./.. T.J; Biotics Research Corporation,
Houston, Texas 77236 [L. B.J; and Department of Radiotherapy, Shanghai Cancer Hospital, The People's Republic of China [M-Z. F.]
ABSTRACT
The purpose of these studies was to quantify the effects of radiation
given to mouse lungs at intervals up to 6 months after injection of the
maximally tolerated dose of cyclophosphamide. In one set of experiments
a single i.p. injection of 300 mg/kg of cyclophosphamide was followed at
either 1, 3, or 6 months by a range of single doses of -y-rays delivered to
the whole thorax only. In a second set of experiments mice were given
five daily i.p. injections of cyclophosphamide, 100 mg/kg, followed at I,
3, and 6 months by a range of fractionated doses of X-rays. Breathing
rate, histology, and mortality were used to assess lung damage. These
data were compared with age-matched animals given either the drug
alone or single doses of radiation alone. Dose-response curves of lethality
were constructed and fitted by a logit program, and 50% lethal doses
with 95% confidence limits were determined at monthly intervals after
irradiation. Dose enhancement factors were then calculated at this isoeffect for the mice given the drug and radiation. Deaths from radiation
pneumonitis occurred as early as 6 weeks in mice given cyclophosphamide
before irradiation; few deaths occurred after 26 weeks. However, in the
mice given radiation alone, deaths from pneumonitis did not occur before
12 weeks. Cyclophosphamide given as either single doses or fractionated
doses at all three times before irradiation enhanced radiation pneumonitis
in mouse lung. Dose enhancement factors of 1.2, 1.4, and 1.3 were
obtained when single doses of radiation followed single doses of cyclo
phosphamide at 1,3, and 6 months, respectively. The dose enhancement
factor for radiation pneumonitis after the fractionated exposures was
less, 1.1, and was independent of time between the two treatments. An
enhancement factor of 1.2 was observed for the later wave of lung damage
in those few studies available for analysis at this time. These data clearly
show that prior treatment of the animal with cyclophosphamide signifi
cantly reduces the radiation dose that can be given to the lung for as long
as 6 months after drug treatment. In addition, lung damage occurred
sooner when the drug was given prior to irradiation. These data indicate
that the lung will be sensitive to retreatment with radiation when a full
tolerance dose of cyclophosphamide precedes radiation.
INTRODUCTION
The primary dose-limiting factor in clinical radiotherapy is
normal tissue toxicity. For tissues that respond long after
treatment is completed, e.g., lung and kidney, few methods are
available to spare these tissues. In addition, many patients
referred for radiotherapy have been treated previously with
chemotherapy, sometimes months or years before referral. The
long-term effects of chemotherapeutic drugs on normal tissues
are not well known. Even less is known about the effects of
chemotherapy and subsequent radiotherapy when time intervals
greater than 4 weeks separate the two treatments.
The purpose of this study was to quantify the effects of
radiation given to mouse lung at intervals up to 6 months after
maximally tolerated doses of cyclophosphamide. These studies
also allowed the time course of tissue effects at long times after
cyclophosphamide treatment to be quantified. Cyclophospha
mide was chosen because of its widespread clinical use and
documented toxicity to lung tissue both in experimental animals
and humans (1-8).
In one set of experiments, a single MTD' of drug was
followed by a range of single doses of X-rays. To make our
study more relevant to clinical situations, another set of exper
iments used a fractionated MTD of drug followed by a range
of fractionated doses of X-rays.
MATERIALS AND METHODS
Animals. Female C3H/Kam mice, bred and maintained in a specificpathogen-free colony, were used. The mice were 8 to 9 weeks old at the
time of initial treatment (either with the drug or with saline), except
for one experiment in which the mice were 13 weeks old. Mice were
housed four or five per cage and given sterilized food and sterilized,
acidified water ad libitum. Some mice treated with cyclophosphamide
developed loss of or growth derangement of incisor teeth. Because these
mice could not masticate hard food pellets, food was soaked in sterile
water until softened. Softened food was administered at least twice a
week and helped prevent loss of mice from starvation. Teeth were
clipped to normal lengths with dental rongeurs on a weekly basis, if
necessary.
Drug. Cyclophosphamide from Mead Pharmaceuticals was used for
all but one experiment, in which Neosar from Adria Labs was used.
The single and fractionated MTDs for cyclophosphamide in our mice
were determined from preliminary LD,<>30-day experiments and de
fined as two-thirds of the LD50 values from dose-response curves. The
MTD for single i.p. doses of cyclophosphamide was determined to be
300 mg/kg. Fractionated doses of cyclophosphamide were administered
as five consecutive daily i.p. injections. A MTD of 110 mg/kg/day for
5 days was determined from a preliminary dose-response experiment
and used for two experiments. In the actual experiments, however, loss
of animals from drug toxicity after the fractionated drug doses reached
25% before irradiation. Therefore, a final experiment used 100 mg/kg/
day for 5 days as the MTD.
Irradiation. All mice were irradiated to the whole thorax without
anesthetic using a specially constructed plastic jig with underarm sup
ports (9). Radiation was delivered from a dual "7Cs source through a
round 2.5-cm portal cut in a 2.5-cm-thick lead block that shielded the
rest of the mouse. The dose rate at the midpoint of the lung was 8.56
Gy/min. The dose to the remainder of the mouse was <5% of the lung
dose.
Radiobiological Assays. Breathing rate, histology, and mortality were
used to assess lung damage. Breathing rates of unanesthetized mice at
rest were measured at 4- to 6-week intervals throughout the experiment
starting from Week 2 after drug administration and Week 2 after
irradiation. The breathing rate assay used most extensively in radiation
studies was used (10-14). Briefly, each mouse was placed in a sealed
plethysmograph chamber with a capacity of about 200 ml, and the
mouse's rate of breathing (BPM) was determined using a capacitance
Received 7/19/89; revised 12/11/89.
The costs of publication of this article were defrayed in part by the payment
of page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1Supported in part by National Cancer Institute Grants CA-06294. CA-38106,
and CA-16672.
1To whom requests for reprints should be addressed, at The University of
Texas M. D. Anderson Cancer Center. Houston. TX 77030.
manometer microphone, as described previously (15). This noninvasive
assay provides a quantitative assessment of lung damage following
radiation as well as after other toxicological insults. The data obtained
from the functional assay have been shown to agree well with histological assessment of damage (10). Breathing rates were calculated as BPM
'The abbreviations used are: MTD. maximally tolerated dose: BPM. breaths
per minute; LD50. 50rr lethal dose; Cy. cyclophosphamide.
2139
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
LATE RESIDUAL LUNG DAMAGE AFTER CVCLOPHOSPHAMIDK
and plotted as a function of time for each dose group.
Mice judged as terminally sick were killed. These deaths were re
corded with other lethalities as they occurred. Any mice that died from
tooth growth abnormalities were excluded from mortality analyses.
Histológica! sections of mouse lungs were prepared from all mice
surviving at the end of each experiment and from mice killed due to
severe respiratory distress or recent death from other causes. Lungs
were fixed by intratracheal infusion of 10% neutral buffered formalin.
Fixed lungs were embedded in paraffin, and 5-^m sections were stained
with hematoxylin/eosin.
11r nut i>limil-illAssays. Blood was collected from mice by a tail vein
nick; the fluid was immediately collected in a heparinized capillary
tube. Twenty ^1of blood (measured by glass micropets) were transferred
to 19.980 ml Isoton II blood diluent. Erythrocytes were lysed by a
commercial blood-lysing liquid (Zapoglobin). A Coulter ZBI counter
was used for leukocyte counts. Hemoglobin was measured by a Coulter
hemoglobinometer. Commercial hematology controls were included in
each run. In most cases, the first dilution (before lysing) was further
diluted for erythrocyte count and hematocrit determination. Because
erythrocyte counts and hematocrits mirrored the hemoglobin levels,
only hemoglobin levels are reported.
Kxperimental Design. Single drug doses were always followed by
single doses of radiation (Experiments S-l, S-3, and S-6), and fraction
ated drug doses were always followed by fractionated radiation (Exper
iments F-l, F-3. and F-6). Two groups of 210 mice each received either
a single i.p. dose or five daily doses of cyclophosphamide as described
above. At 1,3, and 6 months following cyclophosphamide treatment,
groups of 70 mice each were given either single doses of radiation
ranging from 8.5 to 12.75 Gy (Table 1) or 10 equal fractions ranging
from 1.8 to 3.5 Gy/fraction (Table 2) of 7-rays to the whole thorax.
Each dose group contained at least 8 mice. The choice of radiation
doses in both the single and fractionated regimens was designed to
detect cyclophosphamide enhancement factors for lung damage ranging
from 1.0 (no effect) to 1.7 (up to a 70% reduction in radiation dose
following cyclophosphamide treatment). In the fractionated experi
ments, the interval between fractions was 12 h so as to allow "complete"
repair of sublethal radiation damage and the overall treatment time was
5 days to minimize the influence of slow repair on the results (11. 16).
At the 1- and 6- month irradiation time, two groups, each with 60 agematched mice, received either a range of single doses of 7-rays (10.5 to
13.5 Gy) or 10 equal fractions ranging from 2.0 to 3.8 Gy/fraction of
7-rays to the whole thorax and served as age-matched radiation-only
controls. In addition, two groups of eight mice each were given a single
dose or five daily doses of cyclophosphamide. serving as drug controls.
One group of eight mice was given an i.p. injection of saline and shamirradiated, thus serving as age-matched controls.
Statistical Analysis. Dose-response curves of pulmonary lethality
were constructed and fitted by a logit program, and LDW values with
95% confidence limits were determined at monthly intervals after
irradiation. Dose enhancement factors [the ratio of isoeffect dose (i.e.,
i I >,,)for radiation alone to that for drug and radiation combined] with
95% confidence limits were calculated using the method of Pike and
Alper (17) for the mice given before the drug and radiation.
RESULTS
Mortality
Fig. 1 shows a histogram of numbers of mice dead as a
function of time after irradiation for each experiment. Few mice
given either single or fractionated doses of radiation alone died
before 10 weeks. Both of these groups exhibited a clear peak of
deaths between 12 and 16 weeks that declined up to Week 30,
in agreement with published data (14, 15, 18-20). There was a
slight indication of a second wave after 30 weeks. In contrast,
deaths occurred significantly sooner (as early as 6 weeks) in
mice given cyclophosphamide before radiation, particularly
after single doses of both agents. In these mice, mortality peaked
between 8 and 12 weeks and declined slowly thereafter. Exper-
SINGLE DOSES
FRACTIONATED DOSES
rRAYS
ONLY
40
WEEKS POST-IRRADIATION
Fig. 1. Number of animals dead from lung damage as a function of weeks
after single dose (left) or fractionated dose {right) irradiation. Top row. pattern of
death as a function of time after radiation alone; bottom three rows, pattern of
death when cyclophosphamide precedes radiation by 1, 3, or 6 months (S-I, S-3,
and S-6 or F-l, F-3, and F-6, respectively).
iments S-3 and S-6 were terminated at 28 weeks because only
small numbers of mice remained in only two dose groups in
both experiments.
A similar pattern was observed after fractionated doses of
cyclophosphamide and radiation; i.e., deaths occurred sooner
than after radiation alone, particularly when the two treatments
were separated by 1 month (Fig. 1). This trend was less pro
nounced when 3 or 6 months elapsed between Cy and radiation.
Neither the single nor the fractionated doses of drug on their
own killed any mice from lung damage.
Breathing Rate
Single Doses. Fig. 2 shows BPM as a function of time for
selected dose groups from mice given either single doses of
radiation alone (Fig. 2, top) or 3 months (S-3) or 6 months (S6) after a single dose of 300 mg/kg of cyclophosphamide. The
changes in BPM after radiation alone are in agreement with
prev iously published data ( 10-14, 19. 20). Briefly, both the time
of onset and peak response were dose dependent, occurring
sooner after the highest doses. No changes in BPM occurred
before 10 weeks even after doses that were lethal to 100% of
the mice, e.g., 12.75 and 13.5 Gy. After these doses BPM
progressively increased after 10 weeks until all mice succumbed
from severe respiratory distress. After moderate doses, e.g., 12
Gy, BPM decreased from severe respiratory distress. After
moderate doses, e.g., 12 Gy, BPM decreased in those mice
surviving the initial peak response which occurred between 20
and 30 weeks.
The breathing rate of mice given cyclophosphamide at any
2140
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
LATE
r-RAYS
RESIDUAL
LUNG
DAMAGE
AFTER
CYCLOI'HOSPHAMIDE
increase in the breathing rate after all radiation doses, and the
onset and peak response time were similarly shortened.
ONLY
Histology
Radiation Alone. The lungs of mice that were given either
single or fractionated doses of radiation alone and were sacri
ficed before 28 weeks exhibited a typical pneumonitis charac
terized by macrophage infiltrate and edema in the air spaces,
edema of the interstitium, and a mononuclear cell infiltrate in
the alveolar walls. After 28 weeks, pneumonitis was not ob
served. The most striking changes in the lungs of mice sacrificed
between 28 and 52 weeks were multifocal nodular collections
of lymphocytes in the interstitium. accompanied by large
"foamy" cells in the air spaces and collagen accumulation in
this area, forming a focal scar. Long needle-like empty crystal
line spaces resembling cholesterol clefts were found in these
scarred areas.
Cyclophosphamide Alone. The lungs of mice given single or
fractionated doses of cyclophosphamide alone exhibited similar
changes, except at earlier times. A mild pneumonitis was ob
served as soon as 1 month after both drug dosing regimens. By
6 months there was diffuse thickening of the interstitium with
focal collections of "foamy" cells in the air spaces. Subjectively
0
500
400
•¿ 24
WEEK OF CY
0
10
20
1 WEEKS POST r RAYS
r-rays
Fig. 2. Hir.ilium- rait as a function of time after irradiation for vrays alone
(top) or vrays at 3 months (S-3) or 6 months (S-6) after cyclophosphamide.
Bottom, percentage dead as a function of time after irradiation in mice given
cyclophosphamide 6 months before irradiation.
these changes appeared more severe at all times after single
doses than after fractionated doses of cyclophosphamide.
Cyclophosphamide and Radiation. The lungs of mice given
both Cy and radiation exhibited pneumonitis up to 4 months
after radiation. All surviving mice from S-3, S-6, and F-6 were
sacrificed between 7 and 8 months after irradiation. The lungs
of these mice showed a late-resolving pneumonitis with foci of
foamy cells. In a few sections, lesions similar to those found 1
year after radiation alone were found. By 1 year after cyclo
phosphamide and radiation, when all surviving mice from S-I,
F-l, and F-3 were sacrificed, the lungs exhibited only these
later kinds of lesions, which looked exactly like those found in
the lungs of mice sacrificed 1 year after radiation alone. Thus,
the peak of deaths between 8 and 12 weeks in mice given both
drug and radiation was due to pneumonitis, whereas after
radiation alone this same lesion appeared between 12 and 28
weeks. Because few mice given both drug and radiation died
after 12 weeks (see Fig. 1). the time taken for construction of
all dose-response curves for lethality from pneumonitis was 26
weeks, the standard assay time for pneumonitis after radiation
alone.
of the three times before irradiation was increased compared to
the BPM of mice given similar or lower doses of radiation
alone [see Fig. 2 comparing 11.25 G y (Fig. 2, top) with 8.5 and
9.5 Gy at 3 months after Cy (S-3) or 11 Gy given 6 months
after Cy (S-6)]. Although this dose of Cy on its own caused a
significant increase in BPM above that of control mice (average
BPM of 290 and 250, respectively) (see Fig. 2), the BPM
increases in mice given both agents were significantly above
those caused by this dose of drug alone and were dependent on
radiation dose. Cyclophosphamide also shortened the time of
Dose-Response Relationships
onset and time of peak BPM when given at all three times
before irradiation in agreement with the mortality data. For
Dose-response curves were constructed at two times, at 26
example, changes in BPM did not occur before 20 weeks in
weeks
for deaths from pneumonitis and. where possible, at 48
mice given only a single dose of 12.75 Gy (see Fig. 2, top).
weeks
for deaths from the later phase of lung damage. Fig. 3
whereas BPM was increased as soon as 8 weeks in mice given
(top) shows dose-response curves for death at 26 weeks after
cyclophosphamide 3 or 6 months before this same radiation
single doses of radiation alone or at 1, 3, or 6 months after
dose (see Fig. 2, S-3 and S-6). As with radiation alone, BPM
cyclophosphamide. The curves are logit fits to the data and
decreased in some mice surviving after the initial peak response
95% confidence limits are shown. No age dependency for
(see Fig. 2, S-3).
mortality was found after radiation alone, the LD5n values were
Also shown in Fig. 2 (bottom) is mortality as a function of virtually the same (see Table 1). Thus, the two age-matched
time for mice given cyclophosphamide 6 months before radia
control groups were combined for analysis and are presented as
tion, using the same three dose groups shown in the BPM plot one dose response curve. Smooth, well-defined monotonie doseimmediately above. It is clear that increases in BPM occurred
response relationships were produced for mice given radiation
at least 2 weeks before death, in agreement with previously
alone, as well as for mice given cyclophosphamide prior to
radiation. There was a clear displacement of the dose-response
published data for radiation alone (15).
Fractionated Doses. Similar changes in BPM occurred after curves to lower total doses when cyclophosphamide was given
fractionated doses of drug and radiation (data not shown).
at all times before irradiation. This displacement was dependent
on the time between the two treatments, with the 3-month curve
Cyclophosphamide given at all three times caused a significant
2141
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
LATE RESIDUAL LUNG DAMAGE AFTER CYCLOPHOSPHAMIDK
and 2, as well as the DEF for the cyclophosphamide-treated
mice.
100 -
Hematological Changes
8
10
Transient decreases in blood leukocyte counts were observed
in the first month after either single or fractionated doses of
cyclophosphamide. Thus, at the time of all irradiations, leuko
cyte counts in all Cy-treated mice were within control values.
Single doses of radiation alone did not change leukocyte counts
at any time, indicating that any deaths in this arm of the study
were not due to sepsis. Fractionated irradiation caused a tran
sient depression in leukocyte counts (50% of controls) by the
second week after treatment which returned to normal by 2
months. Overall, peripheral leukocyte counts were not altered
in any mice when death occurred. This finding, combined with
histological confirmation of severe lung damage, rules out
sepsis as a cause of death for mice in these experiments.
Except for an initial transient decrease in hemoglobin levels,
blood hemoglobin levels in all treated mice were similar to
those in untreated control mice, indicating that anemia did not
account for any deaths during the experimental periods. Even
mice with tooth growth abnormalities maintained on wetted
feed did not exhibit anemia, suggesting nutritional status was
not grossly inadequate.
12
RETREATMENT DOSE IN Gy
100
48 weeks
O
O
- rays
only
S-1
O
Tooth Abnormalities
50
A few deaths (<1%) were due to loss of one or more sets of
incisors, as described previously (21-23). Loss of incisors ocB
-e8
10
100 -
12
RETREATMENT DOSE IN Gy
Fig. 3. Dose-response curves for pulmonary lethality at 26 weeks from pneumunitis or 48 weeks from the later phase of damage after drug and single doses
of radiation (A). S-1, S-3. and S-6. months between drug and radiation.
being displaced to lower doses than those curves at 1 or 6
months.
Dose-response curves for mortality after fractionated doses
of drug and radiation are shown in Fig. 4 (top). The data are
plotted as a function of total dose. The radiation-alone curve
consists of two experiments from age-matched control mice,
which showed no difference in LD5I>and have been combined
for analysis. Again, the dose-response curves from mice given
cyclophosphamide at all three times prior to radiation are
displaced to lower total doses than those for mice given radia
tion alone. However, there is little time effect for the treatments;
i.e., the dose-response curves at 1, 3, or 6 months cannot be
resolved.
Dose-response curves of mortality for those animals surviving
up to 1 year after single doses or fractionated doses of radiation
are shown in the bottom parts of Figs. 3 (bottom) and 4
(bottom), respectively. Only three time intervals allowed this
analysis, 1 month after single doses and 1 and 3 months after
fractionated doses. As observed at the earlier assay time, cyclo
phosphamide given prior to radiation caused a significant re
duction in the LD<o for this later wave of damage.
LU
O
20
25
30
35
RETREATMENT TOTAL DOSE INGy
48 weeks
100
y-rays
only
tu
o
50
B
15
Isoeffect Data
20
25
30
35
RETREATMENT TOTAL DOSE IN Gy
Radiation isoeffect data have been obtained at the LD51I level
..
. . .. . ..
. . ,
_.
,
, .
from the loglt fits to the lethality data Shown in FlgS. 3 and 4.
These values with 95rr confidence limits are given in Tables 1
F'S- 4- Percentageof mice dead as a function of retreatment total dose after
fractionateddoses of radiation givenat I (F-l). 3 (F-3). or 6 (F-6) months after
cvciophosphamide.Top_dcalhs a, 26 weeksfrom pneumonitis:bottom,deaths at
48 weeksfrom the later phase of lung damage.
2142
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
LATE
RESIDUAL
LUNG
DAMAGE
Table 1 LO50levels and DEFs" for lung death after single doses ofCy and
radiationM
(mos)26
Treatment arm
wkRadiation
aloneS-l
miceS-6
age-matched
miceCombinedRadiation
age-matched
range
c.l.)10.5-13.5
(Gy)
LD«,(Gy)
(95%
AFTER
CYCLOPHOSPHAMIDE
fect data were compared at this time, the standard assay time
for death from radiation pneumonitis. Analyses at earlier times
would not have changed the conclusions.
The data presented here clearly show that cyclophosphamide
given either as a single dose or in a fractionated regimen
significantly reduces the radiation dose that can be given to the
lung for as long as 6 months later, i.e., some of the initial drug
damage is "remembered" by the tissue. After a single dose of
c.l.)1.18(1.08.
12.46(11.9,
12.9)10.5-13.5
12.02(11.57,
12.36)12.22(11.95.
cyclophosphamide, the amount of drug damage remembered
appears to increase up to 3 months (i.e., the radiation LDSI, is
10.54(9.86.
lower at 3 months than at 1 month) with some recovery by 6
1.43)1.44(1.16.2.46)1.26(1.10,
11.20)8.5-12.75
months (the radiation LD5I>is now higher although the 95%
8.67(7.82,
3Experiment S-3
confidence limit overlap). Even at this late retreatment time (6
9.04)9.5-12.75
9.81(9.06.
648
S-6
months) lungs treated previously with cyclophosphamide have
1.72)1.16(1.05. not returned to the sensitivity of normal (i.e., noncyclophos10.23)11.41(11.13.
phamide-treated) lungs.
wkRadiation
aloneCy
Fractionated doses of the drug also caused a decrease in the
11.69)9.66(8.84.
isoeffect dose of the lung to subsequent irradiation, but there
radiationExperiment
+
S-l
1Dose
was less enhancement as compared with the drug given as a
10.15)DEF(95%1.53)
single dose, even though both drug doses represented the MTD
" DEF, dose enhancement factor; c.l.. confidence limits.
for each regimen. In addition, there was little change in radia
tion isoeffect dose at any of the three times tested. These data
curred about 60 days after the single dose of Cy, but not until
indicate that the drug, when given as the MTD in a fractionated
200 days after fractionated dose. The teeth eventually regrew schedule, caused less damage than a single dose alone and that
but upper incisors had to be clipped weekly to prevent excessive
this damage neither progressed nor recovered for as long as 6
elongation. The combination of soft food and weekly clippings
months later.
prevented significant weight loss.
If it is accepted that depletion of a critical population of cells,
"target cells," to a threshold level is necessary before overt
CyExperiment
+
1Experiment S-l
12.5)8.5-12.75
DISCUSSION
The objective of these studies was to quantify the response
of the lung to irradiation at long intervals after treatment with
cyclophosphamide, a widely used chemotherapeutic agent with
well-defined pulmonary toxicity. The doses of drug chosen,
although higher than those used in other studies (2, 3, 24-26),
represented the MTD in our mice. The morphological changes
induced in the lung by cyclophosphamide alone, radiation
alone, or both agents given at various time intervals were the
same qualitatively. These changes appeared sooner after cyclo
phosphamide and radiation, and this was consistent with the
early functional changes and early deaths. Because few mice
given the drug before irradiation died after 26 weeks, all isoefTable 2 LD,a levels and OERfJet
arm26Treatment
in.0(ny)A/
(mos)
tissue damage and dysfunction occurs and that changes in the
radiation isoeffect dose (LD50 in these studies) reflect relative
changes in the number of these target cells (27), then the
changes in LD50 for radiation pneumonitis observed here after
cyclophosphamide treatment can be used to construct a picture
of the time course of depletion and repopulation of the putative
target cells in the lung for radiation. A reduction in the isoeffect
radiation I.I )..,, would represent cell killing and subsequent
depletion from the tissue; an increase would reflect proliferation
and subsequent repopulation by these cells.
Fig. 5 shows the LD50 levels for radiation pneumonitis as a
function of time after cyclophosphamide treatment from only
the single dose data. First, although the single dose of cyclo
phosphamide used in this study (300 mg/kg) was sublethal for
lunx deaths after fractionated doses ofCy and radiation
range (Gy)
Dose/fraction
c.l.)2.9-3.5
wkRadiation
aloneF-l
miceF-6
age-matched
33.03)2.0-3.5
miceCombinedCy
age-matched
+radiationExperiment
F-lExperiment
wkRadiation
aloneCy
radiationExperiment
+
F-lExperiment
F-3Dose
(95%
29.0-35.0
31.63(30.08.
20.0-35.0
31.88(30.31.
33.52)32.19(31.48.
c.l.)1.0(11.10(1.02.
(95%
32.83)1
28.67(27.21.30.11)3 2.5-3.5
25.0-35.0
1.8-3.5
18.0-35.0
28.03(26.80.
1.8-3.5
18.0-35.0
1.37)l.ll(1.03,
28.49(27.31.29.80)29.19(24.23.
1.35)1.19(1.0.
F-3Experiment
F-648
Total dose
29.17)6
1.24)1.13(1.04.
30.55)1
25.03
24.19(22.0,
26.42)DEF
' DEF. dose enhancement factor: c.l.. confidence limits.
2.15)
2143
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
LATE RESIDUAL LUNG DAMAGE AFTER CYCLOPHOSPHAMIDE
13
12
11
o 10
_i
§ 9
1
8
Time After First Treatment (months)
Fig. 5. Radiation LD50 for radiation pneumonilis as a function of months
after a first treatment of cyclophosphamide. D. LD«, for pneumonitis after
radiation alone.
animal survival, on its own it clearly killed some cells; i.e., the
LD50 for whole thorax irradiation was always less in the cyclophosphamide-treated
mice than in control mice (non-drug
treated) (Fig. 5, hatched area). The fluctuations in the LDM>for
radiation pneumonitis with time between the two treatments,
although not significant, suggest that the number of target cells
for radiation did not remain constant but continued to decrease
up to 3 months, with an indication of proliferation by 6 months
after single doses of cyclophosphamide.
In addition, the response of the lung to both treatments
occurred well before the response to radiation alone (see Figs.
1 and 2) and was more consistent with the time the response
was observed after cyclophosphamide alone. This finding, com
bined with the consistently lower LD5(ilevels, indicates that the
lungs of mice previously treated with cyclophosphamide con
tained fewer target cells at the time of irradiation than the lungs
of normal, non-drug-treated mice. Therefore, not only did a
lower radiation dose deplete the cells to a critical level, but it
also took less time to achieve that level, because the tissue was
nearer to the critical threshold level of cell depletion at the time
of exposure.
This hypothesis suggests that radiation and cyclophospha
mide share the same target cells. However, the cellular etiology
and pathogenesis of both radiation- and cyclophosphamideinduced lung damage is unknown and controversial (28-31).
The type II epithelial cell has been implicated as the target cell
for radiation-induced lung damage, at least for the early-ap
pearing pneumonitis (32-34). The target cell in the lung for
cyclophosphamide is even less apparent, but labeling studies
suggest that the type II cell is involved (3, 26). Thus the type II
cell may be the target for both cytotoxic insults.
The differences in latent times for lung damage after radiation
alone or drug treatment alone further support the suggestion
that the type II cell is the common target. Whereas lung damage
is not overtly expressed (as either increased BPM or death)
until at least 3 months, even after a radiation dose that is lethal
to 100% of the mice, cyclophosphamide-induced
lung damage
is expressed within the first 2 months after the dose is admin
istered. These differences in latent times are consistent with
labeling studies which indicate that proliferation of type II cells
occurs within the first week after cyclophosphamide adminis
tration (26), whereas type II cell proliferation occurs much later
(between 1 and 3 months) after irradiation (32). The damage
would therefore occur later after radiation exposure than after
cyclophosphamide treatment.
Whereas we suggest that changes in the radiation dose for
isoeffect simply reflect stem cell depletion, Rubin (30) would
argue that the mechanism of action of these two cytotoxic
insults is different and that they affect either (a) different target
cells or (b) the same target cells but via different pathophysiological mechanisms. However, the consistently lower LD50 lev
els for radiation pneumonitis in mice previously treated with
cyclophosphamide suggests that these two cytotoxic agents
share a common target cell even if they each have more than
one.
Although neither the single dose nor fractionated doses of
cyclophosphamide alone killed any mice, both caused some
lung damage, which was expressed as an increase in breathing
rates significantly above that of age-matched control mice.
These changes in BPM were accompanied by progressive his
tológica! changes similar to those described previously, al
though after lower cyclophosphamide doses. The drug appeared
to produce a chronic, irreversible effect on the lung, similar to
that described by Siemann et al. (3) and Morse et al. (35).
It is interesting that these morphological changes, which
appeared to be progressive, were not accompanied by progres
sive changes in lung function or by a corresponding progressive
increase in radiation sensitivity of the lung, even after a high
single dose of the drug. Rather, lung sensitivity (at the worst)
remained the same between 3 and 6 months after cyclophos
phamide treatment, a time in which the pathology changed
from an alveolitis to an alveolitis accompanied by fibrosis. This
apparent progression in the pathology did not represent a
progression to a more severe lesion. In addition, unlike the
mice given radiation alone, which continued to die for up to 1
year after single or fractionated doses, only a few mice given
both cyclophosphamide and radiation died after 26 weeks in
those three studies available for analysis. Thus, the enhance
ment of this later wave of injury seems to be a result not of
chronic cyclophosphamide damage but rather of chronic radia
tion-induced lung failure.
Considering the implications of these data for the clinical
treatment of patients with recurrent malignancies, it is surpris
ing that few data are available in the literature on this topic.
Only two other studies have assessed the radiation response of
other normal tissues, bone marrow (36) and bladder (37), after
cyclophosphamide treatment. Although both of these studies
used lower drug doses than those used in the present study,
both reported a "significant" reduction in the radiation toler
ance of these two tissues for up to 9 months after cyclophos
phamide treatment, in agreement with our conclusions.
In summary, prior treatment with cyclophosphamide reduces
the radiation dose that can be given to the lung for as long as 6
months after drug treatment. Although the MTD of cyclophos
phamide given as either a single dose or multiple doses en
hanced the sensitivity of the lung to subsequent irradiation,
fractionated doses caused less enhancement. In addition, lung
damage occurred sooner when drug administration preceded
2144
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
LATE RESIDUAL LUNG DAMAGE AFTER CYCLOPHOSPHAMIDF.
irradiation. These data indicate that the lung will be sensitive
to retreatment with radiation when a full "tolerance" dose of
cyclophosphamide
has preceded irradiation.
ACKNOWLEDGMENTS
We wish to thank Lane Watkins and his staff for the supply and care
of the animals used in these studies. We also wish to thank Shelia
Buckner for preparation of this manuscript.
REFERENCES
1. Batist. G., and Andrews. J. L., Jr. Pulmonary toxicityofantincoplastic drugs.
JAMA. 246: 1449-1453. 1981.
2. Collis. C. H. Lung damage from cytotoxic drugs: a review. Cancer Chemother. Pharmacol. IV, /: 17-27. 1980.
3. Siemann, D. W., Maclcr. L., and Penney. D. P. Cyclophosphamide-induced
pulmonary loxicity. Br. J. Cancer, 53: 343-346. 1986.
4. Gould. V. E., and Miller, J. Sclerosing alveolitis induced by cyclophospha
mide. Am. J. Pathol., 81: 513-529, 1975.
5. Mark, G. J.. Lehimgar-Zadeh, A., and Ragsdale, B. D. Cyclophosphamide
pneumonitis. Thorax. 33: 89-93. 1978.
6. Palei, A. R., Shah, R. C., Rhee. H. L., Sassoon, H.. and Rao, K. P.
Cyclophosphamide therapy and interstitial pulmonary fibrosis. Cancer
(Phila.), 38: 1542-1549. 1976.
7. Spector, J. I., Zimbler. H.. and Ross. J. S. Early onset cyclophosphamideinduced interstitial pneumonitis. JAMA. 242: 2852-2854, 1979.
8. Willson, J. K. V. Pulmonary toxicity of antineoplastic drugs. Cancer Treat.
Rep.. 62: 2003-2008. 1978.
9. Travis, E. L., Parkins, C. S.. Holmes. S. J.. and Down, J. D. Effect of
misonida/ole on radiation injury in mouse spinal cord. Br. J. Cancer, 45:
469-473, 1982.
10. Travis, E. L.. Down. J. D.. Holmes. S. J., and Hobson. B. Radiation
pneumonitis and fibrosis in mouse lung assayed by respiratory frequency and
histology. Radiât.Res., 84: 133-143. 1980.
11. Travis, E. L., and Down, J. D. Repair in mouse lung after split doses of Xrays. Radial. Res.. 87: 166-174. 1981.
12. Travis. E. L., Parkins. C. S.. Down. J. D.. Fowler. J. F.. and Thames. H. D.
Repair in mouse lungs between multiple small doses of X-rays. Radial. Res..
9*326-339,
1983.
13. Travis, E. L.. Meistrich. M. L.. Finch-Neimeyer. M. V., Watkins, T. L.. and
Kiss, 1. Late functional and biochemical changes in mouse lung after irradia
tion: differential effects of \\R-272I. Radial. Res.. 103: 219-231, 1985.
14. Travis, E. L., Thames. H. D., Watkins, T. L.. and Kiss, 1. The kinetics of
repair in mouse lung after fractionated radiation. Int. J. Radial. Biol.. 52:
903-919. 1987.
15. Travis. E. L.. Vojnovic. B.. Davies. E. E.. and Hirst, D. G. A plethysmographic method for measuring lung function in locally irradiated mouse lung.
Br. J. Radiol.. 52:67-74, 1979.
16. Field. S. B.. Hornsey. S.. and Kutsutani. Y. Effects of fractionated irradiation
on mouse lung and a phenomenon of slow repair. Br. J. Radiol.. 49: 700707. 1976.
17. Pike, M. C., and Alper. T. A method for determining dose modification
factors. Br. J. Radiol.. 37: 458-462, 1964.
18. Siemann. D. W., Hill. R. P.. and Penney, D. P. Early and late pulmonary
toxicity in mice evaluated 180 days and 420 days following locali/ed lung
irradiation. Radial. Res.. 89: 376-407. 1982.
19. Parkins. C. S.. Fowler, J. F., Maughan. R. L.. and Roper. M. J. Repair in
mouse lung for up to 20 fractions of X-rays or neutrons. Br. J. Radiol.. Stt:
225-241. 1985.
20. Down. J. D.. Easton. D. F.. and Steel. G. G. Repair in the mouse lung during
low dose-rate irradiation. Radiother. Oncol., 6: 29-42. 1986.
21. Orams.
H. J.Res".
Cyclophosphamide-induced
changes in rodent odontogencsis.
Cell Tissue
234: 679-689. 1983.
22. Adatia, A. K. Cytotoxicity of cyclophosphamide in the rat incisor. Br. J.
Cancer. 52:208-218. 1975.
23. Vahlsing. H. L.. Feringa. E. R.. Britten. A. G., and Kinning. W. K. Dental
abnormalities in rats after a single large dose of cyclophosphamide. Cancer
Res.. 55:2199-2202. 1975.
24. Steel. G. G., Adams, K., and Peckham, M. J. Lung damage in C57B1 mice
following thoracic irradiation: enhancement by chemotherap). Br. J. Radici..
52:741-747, 1979.
25. Collis. C. H.. and Steel, G. G. Lung damage in mice from cyclophosphamide
and thoracic irradiation: the effect of timing. Int. J. Radial. Oncol. Biol.
Phys.. 9: 685-689, 1983.
26. Witschi. H.. Godfrey. G., Frome, E., and Lindenschmidt, R. C'. Pulmonary
toxicity of cytoslatic drugs: cell kinetics. Fundament. Appi. Toxicol., 8: 253262. 1987.
27. Thames, H. D.. and Hendry, J. H. Evidence for target-cell depiction as the
determinant of tissue response. In: II. D. Thames and J. H. Hendry (eds.),
Fractionation in Radiotherapy, pp. 22-52. Philadelphia: Taylor & Francis,
1987.
28. Withers. H. R.. Peters, L. J., Thames, H. D.. and Fletcher. G. H. Normal
tissue radioresistance in clinical radiotherapy. In: G. H. Fletcher. C. Nervu,
and H. R. Withers (eds.). Biological Basis and Clinical Implications of Tumor
Radioresistance. pp. 139-152. New York: Masson Publishers. 1984.
29. Hcllman. S.. and Botnick. L. E. Stem cell depletion: an explanation of the
late effects of cytotoxins. Int. J. Radial. Oncol. Biol. Phys., 2: 181-184.
1977.
30. Rubin. P. The Franz Buschkc lecture: late effects of chemotherapy and
radiation therapy: a new hypothesis. Int. J. Radial. Oncol. Biol. Phys.. 10:
5-34. 1984.
31. Collis, C. H. A kinetic model for the pathogencsis of radiation lung damage.
Int. J. Radial. Biol., 42: 253-263. 1982.
32. Coggle. J. E. Proliferation of type II pncumonocytes after X-irradiation. Int.
J. Radial. Biol.. 51: 393-399. 1987.
33. Rubin. P., Siemann. D. W.. Shapiro. D. L., Finkclslcin. J. W., and Penney.
D. P. Surfactant release as an early measure of radiation pneumonitis. Int.
J. Radial. Oncol. Biol. Phys.. 9: 1669-1673, 1983.
34. Shapiro. D. L.. Finkelstein. J. W.. Penney. D. P.. Siemann. D. W.. and
Rubin, P. Sequential effects of irradiation in the pulmonary surfactant
system. Int. J. Radial. Oncol. Biol. Phys., *: 879-882. 1982.
35. Morse. C. C.. Lock, S. S.. Häkkinen.P. J., Haschek, W. M., and Witschi.
H. P. Pulmonary toxicity of cyclophosphamide: A 1-year study. Exp. Mol.
Pathol.. 42:251-260, 1985.
36. Fried. W., and Barone. J. Residual marrow damage following therapy with
cyclophosphamide. Exp. Hematol.. A:610-614. 1980.
37. Edrees, G.. Luts, T., and Stewart, F. A. Bladder damage after treatment with
irradiation and cyclophosphamide. In: E. M. Fielder. J. F. Fowler, J. H.
Hendry. and D. Scott (eds.). Proceedings of the 8th International Congress
of Radiation Research, Edinburgh. July 1987. pp. 272. London: Taylor &
Francis. 1987.
2145
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.
Residual Damage in Mouse Lungs at Long Intervals after
Cyclophosphamide Treatment
Elizabeth L. Travis, Luc Bucci and Mao-Zhong Fang
Cancer Res 1990;50:2139-2145.
Updated version
E-mail alerts
Reprints and
Subscriptions
Permissions
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/50/7/2139
Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Department at pubs@aacr.org.
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/50/7/2139.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
Rightslink site.
Downloaded from cancerres.aacrjournals.org on December 13, 2021. © 1990 American Association for Cancer
Research.